

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

IN RE BRISTOL-MYERS SQUIBB CO.
SECURITIES LITIGATION

File No. 07-CV-5867 (PAC)

**NOTICE OF PENDENCY OF CLASS ACTION AND PROPOSED
SETTLEMENT, SETTLEMENT FAIRNESS HEARING, AND MOTION
FOR ATTORNEYS' FEES AND REIMBURSEMENT OF LITIGATION EXPENSES**

A Federal Court authorized this Notice. This is not a solicitation from a lawyer.

NOTICE OF PENDENCY OF CLASS ACTION: Please be advised that your rights may be affected by a class action lawsuit pending in this Court (the "Consolidated Action") if, during the period from after the close of the market on March 21, 2006, through and including August 8, 2006, you purchased or acquired common stock of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company").

NOTICE OF SETTLEMENT: Please also be advised that the Court-appointed Lead Plaintiff, Ontario Teachers' Pension Plan Board ("Lead Plaintiff"), on behalf of the Class (as defined in ¶1 below), has reached a proposed Settlement of the Consolidated Action for a total of \$125 million in cash that will resolve all claims in the Consolidated Action.

This Notice explains important rights you may have, including your possible receipt of cash from the Settlement. Your legal rights will be affected whether or not you act. Please read this Notice carefully!

1. Description of the Consolidated Action and the Class: This Notice relates to a proposed Settlement of a class action lawsuit pending against Defendant Bristol-Myers and Individual Defendants Peter R. Dolan ("Dolan") and Andrew G. Bodnar ("Bodnar") (the "Defendants"). The proposed Settlement, if approved by the Court, will settle claims of all persons and entities who purchased or acquired Bristol-Myers common stock between after the close of the market on March 21, 2006, through August 8, 2006, inclusive (the "Class Period"), and suffered damages as a result (the "Class").

2. Statement of the Class's Recovery: Subject to Court approval, and as described more fully in ¶¶21-25 below, Lead Plaintiff, on behalf of the Class, has agreed to settle all claims related to the purchase of Bristol-Myers common stock during the Class Period that were or could have been asserted against Defendants and other Released Parties in the Consolidated Action in exchange for a settlement payment of \$125,000,000 (the "Settlement Amount") in cash to be deposited into an interest-bearing escrow account (the "Settlement Fund"). Assuming that all Class Members participate in the Settlement, Lead Counsel's damages expert estimates that the average distribution per affected share of Bristol-Myers common stock will be approximately \$0.42, before the deduction of Court-approved fees, expenses and costs as described herein. Class Members should note, however, that this is only an estimate based on the overall number of potentially damaged shares in the Class. Some Class Members may recover more or less than this estimated amount depending on, among other factors, when and the prices at which their shares were purchased or sold. The Net Settlement Fund (the Settlement Fund less taxes, notice and administration costs, and attorneys' fees and Litigation Expenses awarded to Lead Counsel) will be distributed in accordance with a plan of allocation (the "Plan of Allocation") that will be approved by the Court and will determine how the Net Settlement Fund shall be allocated to the members of the Class. The proposed Plan of Allocation is included in this Notice.

3. Statement of Average Amount of Damages Per Share: The parties do not agree on the average amount of damages per share that would be recoverable if Lead Plaintiff were to prevail. Defendants deny all liability and that any shares of Bristol-Myers common stock were damaged as Lead Plaintiff has alleged. The Parties disagree on, among other things: (i) whether the disclosures challenged in this Consolidated Action were materially false and misleading, (ii) whether the price of Bristol-Myers common stock was inflated as the result of any allegedly false or misleading public statements or omissions by Defendants, and (iii) whether the decline in the price of Bristol-Myers common stock alleged in the Consolidated Action resulted from the disclosure of any information that Lead Plaintiff alleges was wrongfully withheld.

4. Statement of Attorneys' Fees and Expenses Sought: Lead Counsel (as defined in ¶7 below) will apply to the Court for an award of attorneys' fees from the Settlement Fund in an amount not to exceed 20% of the Settlement Amount with interest from the date of funding at the same rate as earned by the Settlement Fund. In addition, Lead Counsel also will apply for the reimbursement of Litigation Expenses paid or incurred in connection with the prosecution and resolution of the Consolidated Action, in an amount not to exceed \$500,000, plus interest from the date of funding at the same rate as earned by the Settlement Fund. Lead Counsel's overall request for reimbursement of

Litigation Expenses may include a request for an award to Lead Plaintiff and/or named plaintiff Minneapolis Firefighters' Relief Association for reimbursement of their reasonable costs and expenses (including lost wages) directly related to their representation of the Class. If the Court approves Lead Counsel's fee and Litigation Expense application, the average cost per affected share will not exceed approximately \$0.09.

5. Identification of Attorneys' Representatives: Lead Plaintiff and the Class are being represented by Salvatore J. Graziano, Esq., of Bernstein Litowitz Berger & Grossmann LLP, the Court-appointed Lead Counsel. Any questions regarding the Settlement should be directed to Mr. Graziano at Bernstein Litowitz Berger & Grossmann LLP, 1285 Avenue of the Americas, New York, NY 10019, (800) 380-8496, blbg@blbglaw.com.

YOUR LEGAL RIGHTS AND OPTIONS IN THE SETTLEMENT:	
REMAIN A MEMBER OF THE CLASS	This is the only way to get a payment. If you wish to be eligible to obtain a payment as a Class Member, you will need to file a Claim Form (which is included with this Notice) postmarked no later than December 30, 2009.
EXCLUDE YOURSELF FROM THE CLASS BY SUBMITTING A WRITTEN REQUEST FOR EXCLUSION SO THAT IT IS RECEIVED NO LATER THAN NOVEMBER 17, 2009.	Get no payment. This is the only option that allows you to ever be part of any other lawsuit against any of the Defendants or other Released Parties concerning the claims that were, or could have been, asserted in this case.
OBJECT TO THE SETTLEMENT BY SUBMITTING WRITTEN OBJECTIONS SO THAT THEY ARE RECEIVED NO LATER THAN NOVEMBER 17, 2009.	Write to the Court and explain why you do not like the Settlement, the proposed Plan of Allocation, or the request for attorneys' fees and reimbursement of expenses. You cannot object to the Settlement unless you are a Class Member and do not exclude yourself.
GO TO THE HEARING ON DECEMBER 8, 2009 AT 2:00 P.M., AND FILE A NOTICE OF INTENTION TO APPEAR SO THAT IT IS RECEIVED NO LATER THAN NOVEMBER 17, 2009.	Ask to speak in Court about the fairness of the Settlement, the proposed Plan of Allocation, or the request for attorneys' fees and reimbursement of expenses.
DO NOTHING	Get no payment. Remain a Class Member. Give up your rights.

WHAT THIS NOTICE CONTAINS

Why Did I Get This Notice?	2
What Is This Case About? What Has Happened So Far?	3
How Do I Know If I Am Affected By The Settlement?	4
What Are The Lead Plaintiff's Reasons For The Settlement?	4
What Might Happen If There Were No Settlement?	5
How Much Will My Payment Be?	5
What Rights Am I Giving Up By Agreeing To The Settlement?	8
What Payment Are The Attorneys For The Class Seeking? How Will The Lawyers Be Paid?	9
How Do I Participate In The Settlement? What Do I Need To Do?	9
What If I Do Not Want To Be A Part Of The Settlement? How Do I Exclude Myself?	9
When And Where Will The Court Decide Whether To Approve The Settlement?	10
Do I Have To Come To The Hearing? May I Speak At The Hearing If I Don't Like The Settlement?	10
What If I Bought Shares On Someone Else's Behalf?	11
Can I See The Court File? Whom Should I Contact If I Have Questions?	11

WHY DID I GET THIS NOTICE?

6. This Notice is being sent to you pursuant to an Order of the United States District Court for the Southern District of New York (the "Court") because you or someone in your family may have purchased or otherwise acquired Bristol-Myers common stock during the Class Period. The Court has directed us to send you this Notice because, as a potential Class Member, you have a right to know about your options before the Court rules on the proposed Settlement of this case. Additionally, you have the right to understand how a class action lawsuit may generally affect your legal rights. If the Court approves the Settlement, a claims administrator selected by Lead Plaintiff and approved by the Court will make payments pursuant to the Settlement after any objections and appeals are resolved.

7. In a class action lawsuit, the Court selects one or more people, known as class representatives, to sue on behalf of all people with similar claims, commonly known as the class or the class members. In this Consolidated Action, the Court has appointed Ontario Teachers' Pension Plan Board to serve as "Lead Plaintiff" under a federal law governing lawsuits such as this one, and approved Lead Plaintiff's selection of the law firm of Bernstein Litowitz Berger & Grossmann LLP ("Lead Counsel") to serve as Lead Counsel in the Consolidated Action. Lead Plaintiff Ontario Teachers' Pension Plan Board and named plaintiff Minneapolis Firefighters' Relief Association are the Class Representatives. A class action is a type of lawsuit in which the claims of a number of individuals are resolved together, thus providing the class members with both consistency and efficiency. Once the class is certified, the Court must resolve all issues on behalf of the class members, except for any persons who choose to exclude themselves from the class. The Court certified the Class on August 18, 2009. (For more information on excluding yourself from the Class, please read "What If I Do Not Want To Be A Part Of The Settlement? How Do I Exclude Myself?," located below.)

8. The Court in charge of this case is the United States District Court for the Southern District of New York, and the case is known as *In re Bristol-Myers Squibb Co. Securities Litigation*. The Judge presiding over this case is the Honorable Paul A. Crotty, United States District Judge. The people who are suing are called plaintiffs, and those who are being sued are called defendants. In this case, the plaintiff is referred to as the Lead Plaintiff, on behalf of itself and the Class, and Defendants are Bristol-Myers and the Individual Defendants.

9. This Notice explains the lawsuit, the Settlement, your legal rights, what benefits are available, who is eligible for them, and how to get them. The purpose of this Notice is to inform you of this case, that it is a class action, how you might be affected, and how to exclude yourself from the Class if you wish to do so. It also is being sent to inform you of the terms of the proposed Settlement, and of a hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the proposed Settlement, the fairness and reasonableness of the proposed Plan of Allocation, and the application by Lead Counsel for attorneys' fees and reimbursement of Litigation Expenses (the "Settlement Hearing").

10. The Settlement Hearing will be held on December 8, 2009 at 2:00 p.m., before the Honorable Paul A. Crotty, at the United States District Court for the Southern District of New York, 500 Pearl Street, Courtroom 20C, New York, New York 10007 to determine:

- (i) whether the proposed Settlement is fair, reasonable, and adequate and should be approved by the Court;
- (ii) whether the Settled Claims against Defendants and the other Released Parties should be dismissed with prejudice as set forth in the Stipulation and Agreement of Settlement (the "Stipulation");
- (iii) whether the proposed Plan of Allocation is fair and reasonable and should be approved by the Court; and
- (iv) whether Lead Counsel's request for an award of attorneys' fees and reimbursement of Litigation Expenses should be approved by the Court.

11. This Notice does not express any opinion by the Court concerning the merits of any claim in the Consolidated Action, and the Court still has to decide whether to approve the Settlement. If the Court approves the Settlement, payments to Authorized Claimants will be made after any appeals are resolved, and after the completion of all claims processing. Please be patient.

WHAT IS THIS CASE ABOUT? WHAT HAS HAPPENED SO FAR?
--

12. Beginning on June 20, 2007, two class action complaints were filed for federal securities laws violations challenging the adequacy of Bristol-Myers' public disclosures concerning its attempts to settle patent litigation with generic pharmaceutical drug company Apotex, Inc. ("Apotex") over its patented blood-thinning medication, Plavix. The complaints named as defendants Bristol-Myers, Dolan and Andrew R.J. Bonfield. The complaints allege that Defendants failed to disclose that the Company had agreed to significant limitations on its damages and patent enforcement rights against Apotex if the regulators rejected the settlement between the companies; that regulators had rejected the initial proposed settlement; and that the renegotiated settlement agreement contained certain alleged secret and unlawful oral representations that were not disclosed to investors or regulators. The complaints allege that, when this information was subsequently disclosed, the price of Bristol-Myers common stock fell and investors suffered damages.

13. In an Order dated September 20, 2007, the Court appointed Ontario Teachers' Pension Plan Board as Lead Plaintiff for the action and approved its selection of Bernstein Litowitz Berger & Grossmann LLP as Lead Counsel for the Class.

14. On October 15, 2007, Lead Plaintiff filed its Amended Class Action Complaint (the "Amended Complaint") asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder on behalf of all persons or entities who purchased or acquired Bristol-Myers common stock during the period from after the close of the market on March 21, 2006, through August 8, 2006, inclusive, and suffered damages as a

result. The Amended Complaint named as defendants Bristol-Myers, Dolan and Bodnar. The Amended Complaint did not name as a defendant Andrew R.J. Bonfield (who was named in the initial complaints), and the claims against him were dismissed without prejudice on October 18, 2007.

15. Beginning on November 12, 2007, Defendants filed separate motions to dismiss the Amended Complaint, which motions Lead Plaintiff opposed on December 17, 2007. Following a hearing on March 12, 2008, on August 19, 2008, the Court issued an Opinion and Order denying Defendants' motions to dismiss. Thereafter, Defendants filed their Answers to the Amended Complaint on September 29 and October 6, 2008.

16. The Parties began discovery in September 2008. Lead Plaintiff issued 52 subpoenas to nonparties; served letters rogatory on Canadian corporation Apotex and its officers; and served document requests on all Defendants. Lead Plaintiff received and reviewed approximately 740,000 pages of documents in response to these subpoenas and requests for documents. Defendant Bristol-Myers also served requests for documents on Lead Plaintiff and named plaintiff Minneapolis Firefighters' Relief Association. Plaintiffs produced approximately 2,000 pages of documents in response to these requests.

17. On October 22, 2008, the Court held a Pretrial Conference and issued a Civil Case Management Plan and Scheduling Order, including an April 22, 2009 deadline for completion of fact discovery. On January 27, 2009, the Court held another Status Conference, following which the parties submitted and the Court ordered a Revised Scheduling Order, extending the deadlines by sixty days.

18. On April 16, 2009, Lead Plaintiff and Bristol-Myers, through counsel, participated in a mediation session before Michael D. Young at JAMS in New York City. Although there was no settlement reached at the conclusion of that session, after additional discussions, and with the continued assistance of Michael D. Young, the Parties reached an agreement in principle to settle this action on the terms set forth in the Stipulation. Following the mediation and before entering into the settlement agreement encompassed in the Stipulation, Lead Counsel conducted additional discovery to confirm the fairness of the Settlement resulting in Lead Plaintiff taking two depositions.

19. On August 18, 2009, the Court preliminarily approved the Settlement, authorized this Notice to be sent to potential Class Members, and scheduled the Settlement Hearing to consider whether to grant final approval to the Settlement.

HOW DO I KNOW IF I AM AFFECTED BY THE SETTLEMENT?

20. If you are a member of the Class, you are subject to the Settlement unless you timely request to be excluded. The Class consists of all persons and entities who purchased or acquired Bristol-Myers common stock during the period from after the close of the market on March 21, 2006, through August 8, 2006, inclusive, and suffered damages as a result. Excluded from the Class are (i) Defendants; (ii) members of the immediate families of individual defendants Dolan and Bodnar; (iii) any person who was an executive officer or director of Bristol-Myers during the Class Period; (iv) any person, firm, trust, corporation, officer, director, or any other individual or entity in which any Defendant has a controlling interest or which is related to or affiliated with any Defendant; (v) any person who actively participated in the alleged wrongdoing at issue; and (vi) the legal representatives, agents, affiliates, heirs, successors-in-interest or assigns of any such excluded party. The Class also does not include those persons and entities who timely request exclusion from the Class pursuant to this Notice (see "What If I Do Not Want To Participate In The Class And The Settlement? How Do I Exclude Myself?," below).

RECEIPT OF THIS NOTICE DOES NOT NECESSARILY MEAN THAT YOU ARE A CLASS MEMBER OR THAT YOU ARE ENTITLED TO RECEIVE PROCEEDS FROM THE SETTLEMENT. IF YOU WISH TO BE ELIGIBLE TO PARTICIPATE IN THE SETTLEMENT, YOU MUST SUBMIT THE ENCLOSED CLAIM FORM POSTMARKED NO LATER THAN DECEMBER 30, 2009.

WHAT ARE THE LEAD PLAINTIFF'S REASONS FOR THE SETTLEMENT?

21. Lead Plaintiff and Lead Counsel believe that the claims asserted against Defendants have merit. Lead Plaintiff and Lead Counsel recognize, however, the expense and length of continued proceedings necessary to pursue their claims against Defendants through trial and appeals, as well as the difficulties in establishing liability for allegations of fraud. Lead Plaintiff and Lead Counsel have taken into account the possibility that the claims asserted in the Amended Complaint might have been dismissed in response to Defendants' anticipated motions for summary judgment, and have considered issues that would have been decided by a jury in the event of a trial of the Consolidated Action, including whether Defendants acted with an intent to mislead investors, whether the alleged misrepresentations or omissions were material to investors, whether all of the Class Members' losses were caused by the alleged misrepresentations or omissions, and the amount of damages. Lead Plaintiff and Lead Counsel have considered the uncertain outcome and trial and appellate risk in complex lawsuits like this one.

22. In light of the amount of the Settlement and the immediacy of recovery to the Class, Lead Plaintiff and Lead Counsel believe that the proposed Settlement is fair, reasonable and adequate, and in the best interests of the Class. Lead Plaintiff and Lead Counsel believe that the Settlement provides a substantial benefit now, namely \$125,000,000 in cash (less the various deductions described in this Notice), as compared to the risk that the claims in the Amended Complaint would produce a similar, smaller, or no recovery after summary judgment, trial and appeals, possibly years in the future. Additionally, the Company has represented that, notwithstanding the fact that it has no continuing legal obligation to maintain its Disclosure Policy and Review Committee ("DPRC") or its Exceptional Circumstance Disclosure Committee ("ECDC"), it intends to maintain in place both the DPRC and the ECDC in the same or similar manner as they presently function and that it has no current plan or intention to discontinue these committees or their roles in the Company's disclosure processes. These committees provide Bristol-Myers with additional disclosure controls. Lead Plaintiff believes that continued use of these committees in the Company's disclosure processes will benefit its shareholders.

23. Defendants have denied the claims asserted against them in the Amended Complaint and deny having engaged in any wrongdoing or violation of law of any kind whatsoever. Defendants have agreed to the Settlement solely to eliminate the burden and expense of continued litigation. Accordingly, the Settlement may not be construed as an admission of Defendants' wrongdoing.

24. Certain criminal charges were filed indirectly relating to the allegations in the Amended Complaint. Defendants and Lead Plaintiff do not anticipate any new criminal charges will be brought against any person relating to the matters alleged in the Amended Complaint. In the event that such charges are brought before the Settlement becomes Final, Lead Plaintiff has the right to terminate the Settlement.

WHAT MIGHT HAPPEN IF THERE WERE NO SETTLEMENT?

25. If there were no Settlement and Lead Plaintiff failed to establish any essential legal or factual element of its claims, neither Lead Plaintiff nor the other members of the Class would recover anything from Defendants. Also, if Defendants were successful in proving any of their defenses, the members of the Class likely would recover substantially less than the amount provided in the Settlement, or nothing at all.

HOW MUCH WILL MY PAYMENT BE?

THE PROPOSED PLAN OF ALLOCATION: GENERAL PROVISIONS

26. Bristol-Myers has agreed to pay or cause to be paid One Hundred and Twenty-Five Million Dollars (\$125,000,000) in cash.

27. After approval of the Settlement by the Court, and upon satisfaction of the other conditions to the Settlement, and upon issuance of a Class Distribution Order, the Net Settlement Fund will be distributed to Authorized Claimants in accordance with the Plan of Allocation.

28. The Settlement Fund will be distributed as follows:

- (i) to pay all federal, state, and local taxes on any income earned by the Settlement Fund and to pay the reasonable costs incurred in connection with determining the amount of, and paying, taxes owed by the Settlement Fund (including reasonable expenses of tax attorneys and accountants);
- (ii) to pay costs and expenses in connection with providing Notice to Class Members and administering the Settlement on behalf of Class Members;
- (iii) to pay attorneys' fees, with interest on such amount, to the extent allowed by the Court;
- (iv) to pay Litigation Expenses incurred in commencing and prosecuting the Action, with interest on such money, to the extent allowed by the Court; and
- (v) to compensate Authorized Claimants with the balance of the Net Settlement Fund in accordance with the Plan of Allocation, subject to an Order of the Court approving the Settlement and the Plan of Allocation (or such other allocation plan as the Court may approve), and subject to such Order becoming Final (meaning that the time for appeal or appellate review of the Order granting final approval has expired, or, if the Order is appealed, that the appeal is either decided without causing a material change in the Order or is upheld on appeal and is no longer subject to appellate review by further appeal or writ of certiorari).

29. Only those Class Members who purchased or acquired Bristol-Myers common stock during the Class Period **AND SUFFERED DAMAGES AS A RESULT**, as set forth below, will be eligible to share in the distribution of the Net Settlement Fund. Each person wishing to participate in the distribution must timely submit a valid Claim Form establishing membership in the Class, and including all required documentation, postmarked no later than December 30, 2009, to the address set forth in the Claim Form that accompanies this Notice. Unless the Court otherwise orders, any Class Member who fails to submit a Claim Form postmarked no later than December 30, 2009 shall be forever barred from

receiving payments pursuant to the Settlement set forth in the Stipulation but will in all other respects remain a Class Member and be subject to the provisions of the Stipulation, including the terms of any Judgment entered and releases given.

30. Payment pursuant to the Plan of Allocation approved by the Court shall be conclusive against all Authorized Claimants. No person shall have any claim against Lead Plaintiff, Lead Counsel, the Claims Administrator or other agent designated by Lead Counsel arising from distributions made substantially in accordance with the Stipulation, the Plan of Allocation, or further orders of the Court. Lead Plaintiff, Defendants, their respective counsel, and all other Released Parties shall have no responsibility or liability whatsoever for the investment or distribution of the Settlement Fund, the Net Settlement Fund, the Plan of Allocation, the determination, administration, calculation, or payment of any claim or nonperformance of the Claims Administrator, the payment or withholding of taxes owed by the Settlement Fund, or any losses incurred in connection therewith, except as otherwise provided in the Stipulation.

31. A "Recognized Loss Amount" will be calculated for each purchase or acquisition of Bristol-Myers common stock during the Class Period, and for which adequate documentation is provided. The calculation of the Recognized Loss Amount will depend upon several factors, including (i) when the Bristol-Myers common stock was purchased or acquired and (ii) whether they were held past the disclosures on July 27, 2006, and/or August 8, 2006, or the conclusion of the 90-day look-back period or, sold during the Class Period or during the 90-day look-back period and, if so, when they were sold. The total of a Claimant's Recognized Loss Amounts shall be the Claimant's "Recognized Claim."

32. **Information Required on the Claim Form:** Each Claim Form must state and provide sufficient documentation for each Authorized Claimant's position in Bristol-Myers common stock as of the close of the market on March 21, 2006, the beginning of the Class Period, and the closing position in Bristol-Myers common stock as of the close of trading on November 3, 2006, the last day of the 90-day look-back period. Each Claim Form also must list and provide sufficient documentation for all transactions in Bristol-Myers common stock as set forth in the Claim Form.

33. The objective of the Plan of Allocation is to equitably distribute the Settlement proceeds to those Class Members who suffered economic losses as a result of the alleged fraud, as opposed to losses caused by market and industry factors or Company-specific factors not related to the alleged fraud. The Plan of Allocation reflects Lead Plaintiff's damages expert's analysis undertaken to that end, including a review of publicly available information regarding Bristol-Myers and analysis regarding the stock price movements. Lead Plaintiff and Lead Counsel, in consultation with Lead Plaintiff's damages expert, have estimated the alleged artificial inflation in Bristol-Myers common stock during the Class Period, as follows, which fairly and reasonably reflects the relevant risks to recovery from Defendants:

For the period from March 21, 2006, through July 26, 2006: \$3.68 per share (maximum inflation).

For the period from July 27, 2006, through August 7, 2006: \$1.59 per share (partial inflation).

For August 8, 2006: The greater of: (a) purchase price *minus* \$21.21 per share, or (b) \$0.00 per share (partial inflation).

34. The Plan of Allocation covers Bristol-Myers common stock only.

35. The Plan of Allocation generally measures the amount of loss that a Class Member can claim under the Settlement for the purpose of making *pro rata* allocations of the cash in the Net Settlement Fund to Class Members who submit acceptable Claim Forms. Recognized Loss Amounts are based on the level of alleged artificial inflation in the price of Bristol-Myers common stock at the time of purchase or acquisition and at the time of sale or other disposal. In this case, Lead Plaintiff alleges that Defendants made false statements and omitted material facts between the close of the market on March 21, 2006, through August 8, 2006, which had the effect of artificially inflating the prices of Bristol-Myers common stock. Defendants deny all such allegations.

36. In order to have recoverable damages, disclosure of the alleged misrepresentations must be the cause of the decline in the price of the security. Alleged corrective disclosures that removed the alleged artificial inflation from the price of Bristol-Myers common stock occurred on July 27, 2006, and August 8, 2006 (the "Corrective Disclosure Dates"). Accordingly, in order to have been damaged by the alleged fraud:

- (i) a Bristol-Myers common stock share purchased or otherwise acquired during the Class Period after the close of the market on March 21, 2006, through July 26, 2006, must be held at least until July 27, 2006, the day of the first corrective disclosure; and
- (ii) a Bristol-Myers common stock share purchased or otherwise acquired from July 27, 2006, through August 7, 2006, must be held at least until August 8, 2006, the day of the price impact of the second corrective disclosure.

37. If you did not hold Bristol-Myers common stock to the dates indicated, the Recognized Loss Amount for those shares of Bristol-Myers common stock is \$0. The Recognized Loss Amount for those transactions will be calculated as zero because it has been determined that the alleged artificial inflation between each disclosure and arising from the circumstances underlying the allegations of the Amended Complaint was constant, therefore if you purchased and sold only between disclosures any loss suffered is not compensable under the federal securities laws.

SPECIFIC RECOGNIZED LOSS AMOUNTS

Bristol-Myers Common Stock Recognized Loss Amounts

- (i) For shares purchased or acquired between after the close of the market on March 21, 2006, and August 8, 2006, inclusive, and held at least until August 8, 2006, the Recognized Loss Amount is the **lesser of**:
 - (a) the purchase price *minus* the 90-day look-back price on the date of sale as set forth in Table A included below (or the 90-day look-back price on November 3, 2006, if the share security was not sold prior to November 3, 2006); or
 - (b) the amount of alleged artificial inflation per share on the date of purchase or acquisition as set forth above.
- (ii) For shares purchased or acquired between after the close of the market on March 21, 2006, and July 26, 2006, inclusive, and sold at a loss between July 27, 2006, and August 7, 2006, inclusive, the Recognized Loss Amount is the **lesser of**:
 - (a) the purchase price *minus* sales price; or
 - (b) the amount of alleged artificial inflation per share on the date of purchase or acquisition as set forth above *minus* the amount of alleged artificial inflation per share on the date of sale as set forth above.

38. An Authorized Claimant's Recognized Loss Amounts shall be the basis for his, her, or its allocated *pro rata* portion of the Net Settlement Fund.

ADDITIONAL PROVISIONS

39. The Net Settlement Fund will be allocated among all Authorized Claimants.

40. Each Authorized Claimant shall recover his, her, or its Recognized Claim. If the sum total of Recognized Claims of all Authorized Claimants who are entitled to receive payment out of the Net Settlement Fund is greater than the Net Settlement Fund, however, each such Authorized Claimant shall be allocated *pro rata* shares of the Net Settlement Fund based on his, her, or its Recognized Claim as compared to the total Recognized Claims of all Authorized Claimants.

41. If the Net Settlement Fund exceeds the sum total amount of the Recognized Claims of all Authorized Claimants entitled to receive payment out of the Net Settlement Fund, the excess amount in the Net Settlement Fund shall be distributed *pro rata* to all Authorized Claimants entitled to receive payment.

42. A payment to any Authorized Claimant that would amount to less than \$10.00 in total will not be included in the calculation of the Net Settlement Fund, and no payment to these Class Members will be distributed.

43. The amount of a Class Member's Recognized Claim as computed above is not intended to be an estimate of what a Class Member might have been able to recover at trial, and it is not an estimate of the amount that will be paid pursuant to this Settlement. Instead, this computation is only a method to weigh Class Members' claims against one another. Each Authorized Claimant will receive *pro rata* shares of the Net Settlement Fund based on his, her, or its Recognized Claim.

44. If a Class Member has more than one purchase/acquisition or sale of Bristol-Myers common stock during the Class Period, all purchases/acquisitions and sales shall be matched on a First-In-First-Out ("FIFO") basis. Class Period sales will be matched first against any Bristol-Myers common stock held at the beginning of the Class Period, and then against purchases/acquisitions in chronological order, beginning with the earliest purchase/acquisition made during the Class Period. Purchases, acquisitions, and sales of Bristol-Myers common stock shall be deemed to have occurred on the "contract" or "trade" date as opposed to the "settlement" or "payment" date. The receipt or grant by gift, inheritance or operation of law of Bristol-Myers common stock during the Class Period shall not be deemed a purchase, acquisition or sale of these shares of Bristol-Myers common stock for the calculation of an Authorized Claimant's Recognized Claim nor shall the receipt or grant be deemed an assignment of any claim relating to the purchase/acquisition of such Bristol-Myers common stock shares unless (i) the donor or decedent purchased or acquired such Bristol-Myers common stock shares during the Class Period; (ii) no Claim Form was submitted by or on behalf of the donor, on behalf of the decedent, or by anyone else with respect to such shares; and (iii) it is specifically so provided in the instrument of gift or assignment.

45. The date of covering a "short sale" is deemed to be the date of purchase or acquisition of Bristol-Myers common stock. The date of a "short sale" is deemed to be the date of sale of Bristol-Myers common stock shares. In accordance with the Plan of Allocation, however, the Recognized Loss Amount on "short sales" is zero.

46. To the extent a Claimant had a market gain from his, her, or its overall transactions in Bristol-Myers common stock during the Class Period, the value of the Recognized Claim will be zero. Such Claimants will in any event be bound by the Settlement. To the extent a Claimant suffered an overall market loss on his, her, or its overall transactions in Bristol-Myers common stock during the Class Period, but that market loss was less than the Recognized Claim calculated above, then the Recognized Claim shall be limited to the amount of the actual market loss.

47. For purposes of determining whether a Claimant had a market gain from his, her, or its overall transactions in Bristol-Myers common stock during the Class Period or suffered a loss, the Claims Administrator shall: (i) total the amount the Claimant paid for all Bristol-Myers common stock purchased/acquired during the Class Period (the "Total Purchase Amount"); (ii) match any sales of Bristol-Myers common stock during the Class Period and sales during the 90-day look-back period first against the Claimant's opening position in Bristol-Myers common stock (the proceeds of those sales will not be considered for purposes of calculating gains or losses); (iii) total the amount received for the remaining sales of Bristol-Myers common stock during the Class Period and during the 90-day look-back period that can be matched against Class Period purchases (the "Sales Proceeds"), and (iv) ascribe a holding price for shares purchased/acquired during the Class Period and still held at the end of the 90-day look-back period, with such holding price being \$23.56 per share (the "Holding Value"). The difference between (x) the Total Purchase Amount [(i) above] and (y) the sum of the Sales Proceeds [(iii) above] and the Holding Value [(iv) above] will be deemed a Claimant's market gain or loss on his, her, or its overall transactions in Bristol-Myers common stock during the Class Period.

48. The Court has reserved jurisdiction to allow, disallow, or adjust on equitable grounds the Claim of any Class Member.

49. The Plan of Allocation set forth herein is the plan that is being proposed by Lead Plaintiff and Lead Counsel to the Court for approval. The Court may approve this plan as proposed or it may modify the Plan of Allocation without further notice to the Class. All Orders regarding a modification of the Plan of Allocation will be posted on the settlement website, www.bristolmyerssecuritieslitigation.com.

50. Each Claimant shall be deemed to have submitted to the jurisdiction of the United States District Court for the Southern District of New York with respect to his, her or its Claim Form.

51. Persons and entities that exclude themselves from the Class will not be eligible to receive a distribution from the Net Settlement Fund and should not submit Claim Forms.

WHAT RIGHTS AM I GIVING UP BY AGREEING TO THE SETTLEMENT?

52. If the Settlement is approved, the Court will enter a judgment (the "Judgment"). The Judgment will dismiss with prejudice the claims against the Defendants and will provide that Lead Plaintiff and all other Class Members shall be deemed to have – by operation of the Judgment shall have – fully and finally released, waived, discharged, and dismissed each and every Settled Claim (as defined below), including Unknown Claims (as defined below) against the Released Parties (as defined below).

53. "Settled Claims" means any and all claims and causes of action of every nature and description, whether known or Unknown, whether arising under federal, state, common or foreign law, that Lead Plaintiff or any other member of the Class (a) asserted in the Amended Complaint, or (b) could have asserted in any forum that arise out of or are based upon the allegations, transactions, facts, matters or occurrences, representations or omissions involved, set forth, or referred to in the Amended Complaint and that relate to the purchase of Bristol-Myers common stock during the Class Period. Notwithstanding the foregoing, "Settled Claims" does not include the claims asserted in any derivative action based on similar allegations, including but not limited to the action captioned *Steven W. Sampson, Trustee v. Robinson, et al.*, 07-6890, previously filed in this Court. Additionally, "Settled Claims" does not include claims relating to the enforcement of the Settlement.

54. "Released Parties" means Defendants, and any and all of their respective officers, directors, employees, agents and attorneys.

55. "Unknown Claims" means any and all Settled Claims that Lead Plaintiff or any Class Member does not know or suspect to exist in his, her or its favor at the time of the release of the Released Parties, and any Released Parties' Claims (as defined below) that any Released Party does not know or suspect to exist in his, her or its favor, which if known by him, her or it might have affected his, her or its decision(s) with respect to the Settlement. With respect to any and all Settled Claims and Released Parties' Claims, upon the Effective Date, the Lead Plaintiff and the Released Parties shall expressly waive, and each Class Member shall be deemed to have waived, and by operation of the Judgment shall have expressly waived, any and all provisions, rights and benefits conferred by any law of any state or territory of the United States, or principle of common law, that is similar, comparable, or equivalent to Cal. Civ. Code § 1542, which provides:

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.

Lead Plaintiff and the Released Parties acknowledge, and Class Members by operation of law shall be deemed to have acknowledged, that the inclusion of "Unknown Claims" in the definition of Settled Claims and Released Parties' Claims was separately bargained for and was a key element of the Settlement.

56. The Judgment also will provide that Defendants and each of the other Released Parties, on behalf of themselves, their heirs, executors, administrators, predecessors, successors, and assigns shall be deemed to have – and by operation of the Judgment shall have – fully, finally, and forever released, waived, discharged and dismissed as against all plaintiffs in the action, and their officers, directors, employees, agents and attorneys, and all other Class Members, any and all claims and causes of action of every nature and description, whether known or Unknown, whether arising under federal, state, common or foreign law, that arise out of or relate in any way to the institution, prosecution, or settlement of the claims against the Defendants (“Released Parties’ Claims”). “Released Parties’ Claims” does not include claims relating to enforcement of the Settlement.

WHAT PAYMENT ARE THE ATTORNEYS FOR THE CLASS SEEKING?
HOW WILL THE LAWYERS BE PAID?

57. Lead Counsel has not received any payment for its services in pursuing claims against Defendants on behalf of the Class, nor has Lead Counsel been reimbursed for its out-of-pocket expenses. Before final approval of the Settlement, Lead Counsel intends to apply to the Court for an award of attorneys’ fees from the Settlement Fund in an amount not to exceed 20% of the Settlement Amount, plus interest from the date of funding at the same rate as earned by the Settlement Fund. At the same time, Lead Counsel also intends to apply for the reimbursement of Litigation Expenses not to exceed \$500,000, plus interest from the date of funding at the same rate as earned by the Settlement Fund. Lead Counsel’s overall request for reimbursement of Litigation Expenses may include a request for an award to Lead Plaintiff and/or named plaintiff Minneapolis Firefighters’ Relief Association for reimbursement of their reasonable costs and expenses (including lost wages) directly related to their representation of the Class. The Court will determine the amount of the awards.

HOW DO I PARTICIPATE IN THE SETTLEMENT? WHAT DO I NEED TO DO?

58. If you purchased or otherwise acquired Bristol-Myers common stock during the period between after the close of the market on March 21, 2006, through August 8, 2006, inclusive, and you are not excluded by the definition of the Class and you do not elect to exclude yourself from the Class, then you are a Class Member. You will be bound by the proposed Settlement if the Court approves it, and by any judgment or determination of the Court affecting the Class. If you are a Class Member, you must submit a Claim Form and supporting documentation to establish your entitlement to share in the Settlement. A Claim Form is included with this Notice, or you may go to the website maintained by the Claims Administrator for the Settlement to request that a Claim Form be mailed to you. The website is www.bristolmyerssecuritieslitigation.com. You may also request a Claim Form by calling toll-free 1-866-358-3481. Copies of the Claim Form can also be downloaded from Lead Counsel’s website at www.blbglaw.com. Those who exclude themselves from the Class, and those who do not submit timely and valid Claim Forms with adequate supporting documentation will not be entitled to share in the Settlement. Please retain all records of your ownership of, or transactions in Bristol-Myers common stock, as they may be needed to document your Claim.

59. As a Class Member, you are represented by Lead Plaintiff and Lead Counsel, unless you enter an appearance through counsel of your own choice at your own expense. You are not required to retain your own counsel, but if you choose to do so, such counsel must file a notice of appearance on your behalf and must serve copies of his or her notice of appearance on the attorneys listed in the section entitled, “When and Where Will the Court Decide Whether to Approve the Settlement?,” below.

60. If you do not wish to remain a Class Member, you may exclude yourself from the Class by following the instructions in the section entitled, “What If I Do Not Want To Be A Part Of The Class And The Settlement? How Do I Exclude Myself?,” below.

61. If you wish to object to the Settlement or any of its terms, the proposed Plan of Allocation, or Lead Counsel’s application for attorneys’ fees and reimbursement of Litigation Expenses, and if you do not exclude yourself from the Class, you may present your objections by following the instructions in the section entitled, “When and Where Will the Court Decide Whether to Approve the Settlement?,” below.

WHAT IF I DO NOT WANT TO BE A PART OF THE SETTLEMENT?
HOW DO I EXCLUDE MYSELF?

62. Each Class Member will be bound by all determinations and judgments in this lawsuit, including those concerning the Settlement, whether favorable or unfavorable, unless such person or entity mails, by first-class mail (or its equivalent outside the U.S.), or otherwise delivers a written Request for Exclusion from the Class, addressed to *In re Bristol-Myers Squibb Co. Securities Litigation - EXCLUSIONS*, - c/o The Garden City Group, Inc., PO Box 9515, Dublin, OH 43017-4815. The exclusion request must be *received* no later than November 17, 2009. You will not be able to exclude yourself from the Class after that date. Each Request for Exclusion must (i) state the name and address of the person or entity requesting exclusion; (ii) state that such person or entity “requests exclusion from the Class in *In re Bristol-Myers Squibb Co. Securities Litigation*, 07-CV-5867 (PAC)”; (iii) be signed by the person or entity requesting

exclusion; (iv) provide a telephone number for that person or entity; and (v) provide the date(s), price(s), and number(s) of shares of all purchases, acquisitions, and sales of Bristol-Myers common stock during the Class Period. Requests for exclusion will not be valid if they do not include the information set forth above and are not received within the time stated above, unless the Court otherwise determines.

63. If you do not want to be part of the Class, you must follow these instructions for exclusion even if you have pending, or later file, another lawsuit, arbitration, or other proceeding relating to any Settled Claims.

64. If a person or entity requests to be excluded from the Class, that person or entity will not receive any benefit provided for in the settlement.

65. Bristol-Myers may on behalf of all Defendants terminate the Settlement if requests for exclusion are received from potential Class Members whose allegedly damaged shares of Bristol-Myers common stock, in the aggregate, exceed an amount stated in a Supplemental Agreement.

<p>WHEN AND WHERE WILL THE COURT DECIDE WHETHER TO APPROVE THE SETTLEMENT? DO I HAVE TO COME TO THE HEARING? MAY I SPEAK AT THE HEARING IF I DON'T LIKE THE SETTLEMENT?</p>

66. **If you do not wish to object in person to the proposed Settlement, proposed Plan of Allocation, and/or the application for attorneys' fees and reimbursement of Litigation Expenses, you do not need to attend the Settlement Hearing. You can object to or participate in the Settlement without attending the Settlement Hearing.**

67. The Settlement Hearing will be held on December 8, 2009 at 2:00 p.m. before the Honorable Paul A. Crotty, at the United States District Court for the Southern District of New York, 500 Pearl Street, Courtroom 20C, New York, NY 10007. The Court reserves the right to approve the Settlement, the Plan of Allocation or the request for attorneys' fees and reimbursement of Litigation Expenses at or after the Settlement Hearing without further notice to the members of the Class.

68. Any Class Member who does not submit a valid exclusion that is *received* no later than November 17, 2009 may object to the Settlement, the Plan of Allocation, or Lead Counsel's request for an award of attorneys' fees and reimbursement of Litigation Expenses. Objections or oppositions must be in writing. You must file any written objection or opposition, together with copies of all other papers (including proof of all purchases or acquisitions of Bristol-Myers common stock during the Class Period) and briefs, with the Clerk's Office at the United States District Court for the Southern District of New York at the address set forth below on or before November 17, 2009. You must also serve the papers on Lead Counsel for the Class at the address set forth below so that the papers are *received* on or before November 17, 2009.

Clerk's Office

UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK
Clerk of the Court
500 Pearl Street
New York, NY 10007-1312

Lead Counsel for the Class

BERNSTEIN LITOWITZ BERGER
& GROSSMANN LLP
Salvatore J. Graziano, Esq.
1285 Avenue of the Americas
New York, NY 10019

Counsel for Bristol-Myers

DEBEVOISE & PLIMPTON LLP
Sean Hecker, Esq.
919 Third Avenue
New York, NY 10022

69. The filing must demonstrate your membership in the Class, including the number of shares of Bristol-Myers common stock purchased or otherwise acquired or sold during the Class Period and the price(s) paid and received. You may not object to the Settlement or any aspect of it, if you are not a Class Member or if you excluded yourself from the Class.

70. You may file a written objection without having to appear at the Settlement Hearing. You may not appear at the Settlement Hearing to present your objection, however, unless you first filed and served a written objection in accordance with the procedures described above, unless the Court orders otherwise.

71. If you wish to be heard orally at the hearing in opposition to the approval of the Settlement, the Plan of Allocation, or Lead Counsel's request for an award of attorneys' fees and reimbursement of expenses, and if you have filed and served a timely written objection as described above, you also must notify the above counsel on or before

November 17, 2009 concerning your intention to appear. Persons who intend to object and desire to present evidence at the Settlement Hearing must include in their written objections the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the hearing.

72. You are not required to hire an attorney to represent you in making written objections or in appearing at the Settlement Hearing. If you decide to hire an attorney, which will be at your own expense, however, he or she must file a notice of appearance with the Court and serve it on Lead Counsel so that the notice is received on or before November 17, 2009.

73. The Settlement Hearing may be adjourned by the Court without further written notice to the Class. If you intend to attend the Settlement Hearing, you should confirm the date and time with Lead Counsel.

Unless the Court orders otherwise, any Class Member who does not object in the manner described above will be deemed to have waived any objection and shall be forever foreclosed from making any objection to the proposed Settlement, the proposed Plan of Allocation, or Lead Counsel's request for an award of attorneys' fees and reimbursement of Litigation Expenses. Class Members do not need to appear at the hearing or take any other action to indicate their approval.

WHAT IF I BOUGHT SHARES ON SOMEONE ELSE'S BEHALF?

74. If you purchased or otherwise acquired Bristol-Myers common stock during the Class Period for the beneficial interest of a person or organization other than yourself, you must either (i) send a copy of this Notice to the beneficial owner of such Bristol-Myers common stock, postmarked no later than fourteen (14) days after you receive this Notice, or (ii) provide the names and addresses of such persons no later than fourteen (14) days after you receive this Notice to *In re Bristol-Myers Squibb Co. Securities Litigation*, c/o The Garden City Group, Inc., PO Box 9515, Dublin, OH 43017-4815. If you choose the first option, upon such mailing, you must send a statement to the Claims Administrator confirming that the mailing was made as directed, and you must retain the list of names and addresses for use in connection with any possible future notice to the Class. If you choose the second option, the Claims Administrator will send a copy of the Notice to the beneficial owner. Upon full compliance with these directions, such nominees may seek reimbursement of their reasonable expenses actually incurred, by providing the Claims Administrator with proper documentation supporting the expenses for which reimbursement is sought. Copies of this Notice may also be obtained from the Claims Administrator's website www.gardencitygroup.com, or by calling toll-free 1-866-358-3481, may be downloaded from the settlement website, www.bristolmyerssecuritieslitigation.com, or from Lead Counsel's website, www.blbglaw.com.

CAN I SEE THE COURT FILE? WHOM SHOULD I CONTACT IF I HAVE QUESTIONS?

75. This Notice contains only a summary of the terms of the proposed Settlement. More detailed information about the matters involved in the Consolidated Action is available at www.bristolmyerssecuritieslitigation.com, including, among other documents, copies of the Stipulation, Claim Form, the Amended Complaint, the Court's Order on the Defendants' motions to dismiss the Consolidated Action and the Answers of Defendants. Copies of the Court-filed documents are also available for review during regular business hours at the address listed above. All inquiries concerning this Notice or the Claim Form should be directed to:

In re Bristol-Myers Squibb Co. Securities Litigation
c/o The Garden City Group, Inc.
P.O. Box 9515
Dublin, OH 43017-4815

OR

Salvatore J. Graziano, Esq.
BERNSTEIN LITOWITZ BERGER
& GROSSMANN LLP
1285 Avenue of the Americas
New York, NY 10019
1-800-380-8496
blbg@blbglaw.com

Lead Counsel

**DO NOT CALL OR WRITE THE COURT OR THE OFFICE OF THE CLERK OF COURT
REGARDING THIS NOTICE.**

Dated: September 1, 2009

By Order of the Clerk of Court
United States District Court
for the Southern District of New York

TABLE A

Date	Closing Price	90-Day Lookback Price Per Share		Date	Closing Price	90-Day Lookback Price Per Share
08/08/06	\$21.21	\$21.21		09/22/06	\$25.06	\$22.58
08/09/06	\$21.12	\$21.17		09/25/06	\$25.07	\$22.65
08/10/06	\$20.83	\$21.05		09/26/06	\$25.10	\$22.72
08/11/06	\$20.24	\$20.85		09/27/06	\$25.00	\$22.79
08/14/06	\$20.41	\$20.76		09/28/06	\$24.85	\$22.84
08/15/06	\$20.79	\$20.77		09/29/06	\$24.92	\$22.90
08/16/06	\$21.08	\$20.81		10/02/06	\$24.68	\$22.94
08/17/06	\$21.48	\$20.90		10/03/06	\$24.82	\$22.99
08/18/06	\$21.64	\$20.98		10/04/06	\$24.62	\$23.03
08/21/06	\$21.55	\$21.04		10/05/06	\$24.52	\$23.06
08/22/06	\$21.84	\$21.11		10/06/06	\$24.42	\$23.10
08/23/06	\$21.63	\$21.15		10/09/06	\$24.38	\$23.13
08/24/06	\$21.64	\$21.19		10/10/06	\$24.49	\$23.16
08/25/06	\$21.68	\$21.22		10/11/06	\$24.30	\$23.18
08/28/06	\$21.72	\$21.26		10/12/06	\$24.60	\$23.21
08/29/06	\$21.93	\$21.30		10/13/06	\$24.55	\$23.24
08/30/06	\$21.98	\$21.34		10/16/06	\$24.52	\$23.26
08/31/06	\$21.75	\$21.36		10/17/06	\$24.46	\$23.29
09/01/06	\$22.95	\$21.45		10/18/06	\$24.73	\$23.32
09/05/06	\$22.78	\$21.51		10/19/06	\$24.65	\$23.34
09/06/06	\$22.63	\$21.57		10/20/06	\$24.49	\$23.36
09/07/06	\$22.71	\$21.62		10/23/06	\$24.57	\$23.39
09/08/06	\$23.18	\$21.69		10/24/06	\$24.75	\$23.41
09/11/06	\$23.39	\$21.76		10/25/06	\$24.66	\$23.43
09/12/06	\$24.32	\$21.86		10/26/06	\$24.53	\$23.45
09/13/06	\$24.81	\$21.97		10/27/06	\$24.69	\$23.47
09/14/06	\$24.68	\$22.07		10/30/06	\$24.33	\$23.49
09/15/06	\$24.92	\$22.17		10/31/06	\$24.75	\$23.51
09/18/06	\$24.88	\$22.27		11/01/06	\$24.62	\$23.53
09/19/06	\$24.71	\$22.35		11/02/06	\$24.47	\$23.54
09/20/06	\$24.89	\$22.43		11/03/06	\$24.53	\$23.56
09/21/06	\$24.71	\$22.50				